Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T cell responses in glioblastoma.

Publication

Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T cell responses in glioblastoma.

Journal Paper/Review - Oct 13, 2022

Wang Jian, Weiss Tobias, Neidert Marian C, Toussaint Nora C, Naghavian Reza, Moreno Sellés Carla, Foege Magdalena, Tomas Ojer Paula, Medici Gioele, Jelcic Ivan, Schulz Daniel, Rushing Elisabeth, Dettwiler Susanne, Schrörs Barbara, Shin Joo Heon, McKay Ron, Wu Catherine J, Lutterotti Andreas, Sospedra Mireia, Moch Holger, Greiner Erich F, Bodenmiller Bernd, Regli Luca, Weller Michael, Roth Patrick, Martin Roland

Citation

Wang J, Weiss T, Neidert M, Toussaint N, Naghavian R, Moreno Sellés C, Foege M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrörs B, Shin J, McKay R, Wu C, Lutterotti A, Sospedra M, Moch H, Greiner E, Bodenmiller B, Regli L, Weller M, Roth P, Martin R. Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T cell responses in glioblastoma. Clin Cancer Res 2022

Type

Journal Paper/Review (English)

Journal

Clin Cancer Res 2022

Publication Date

Oct 13, 2022

Issn Electronic

1557-3265

Brief description/objective

The low mutational load of some cancers is considered one reason for the difficulties to develop effective tumor vaccines. To overcome this problem, we developed a strategy to design neopeptides through single amino acid mutation to enhance their immunogenicity.